The short answer
Retatrutide's clinical timeline began with Phase 1 first-in-human dosing around 2020 and Phase 2 results in the New England Journal of Medicine in 2023. The Phase 3 TRIUMPH programme launched in 2023 and reported across December 2025 to July 2026, with all pivotal trials meeting their primary endpoints. An FDA filing has been signalled for Q1 2027.
Key facts
- Phase 1
- ~2020 (NCT04143802)
- Phase 2
- Published NEJM 2023 (Jastreboff et al.)
- Phase 3 launch
- 2023 (TRIUMPH programme)
- First Phase 3 readout
- TRIUMPH-4, December 2025
- Pivotal readout
- TRIUMPH-1, 21 May 2026
- Comorbid populations
- TRIUMPH-2 and -3, July 2026
- Signalled FDA filing
- Q1 2027
What is the TRIUMPH programme?
TRIUMPH is Eli Lilly's Phase 3 development umbrella for retatrutide, comprising multiple trials across obesity, type 2 diabetes and cardiovascular populations, with more than 5,800 participants enrolled in total. Registrations are listed on ClinicalTrials.gov.
How the Phase 3 readouts landed
TRIUMPH-4 reported first in December 2025. The pivotal obesity study, TRIUMPH-1, reported topline results on 21 May 2026 across 2,339 randomised adults. TRIUMPH-2, in obesity with type 2 diabetes, and TRIUMPH-3, in severe obesity with established cardiovascular disease, both reported in July 2026 and both met their primary endpoints.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What comes next
Further Phase 3 readouts were expected across 2026, including maintenance-dosing studies examining what happens when the dose is reduced or withdrawn. Lilly has signalled an FDA Biologics License Application in the first quarter of 2027; regulatory review commonly adds a year or more, and retatrutide remains investigational throughout.
Quick reference
| Stage | Date | Outcome |
|---|---|---|
| Phase 1 | 2020 | First-in-human, single/multiple ascending doses |
| Phase 2 | 2022-2023 | Obesity + T2D; NEJM publication 2023 |
| TRIUMPH-4 | Dec 2025 | First Phase 3 readout |
| TRIUMPH-1 | 21 May 2026 | 28.3% mean reduction at 80 wks (12 mg) |
| TRIUMPH-2 / -3 | July 2026 | Both met primary endpoints |
| FDA filing | Q1 2027 (planned) | Not yet submitted |
Frequently asked questions
How long are Phase 3 trials?
TRIUMPH trials run multi-year. TRIUMPH-1 had its primary analysis at 80 weeks with a 104-week extension.
Is the Phase 3 programme finished?
The pivotal trials have reported, but the programme continues. Maintenance-dosing studies were still outstanding.
When could retatrutide reach the market?
No date exists. A filing was signalled for Q1 2027, and review typically takes a year or more with no guaranteed outcome.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- RefJastreboff et al., NEJM 2023 (Phase 2)nejm.org
- RefTRIUMPH-1 topline results: Eli Lillyinvestor.lilly.com
- RefTwo additional Phase 3 obesity trials. Eli Lillyinvestor.lilly.com
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedJastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- Who Develops Retatrutide?Eli Lilly, under the code LY3437943. Why that matters for reading trial data, and why no licensed retatrutide product exists.
- Retatrutide Half-Life: Where It Comes FromThe C20 diacid binds albumin reversibly, supporting once-weekly trial dosing. Why chain length sets duration across the whole incretin family.
- Retatrutide Chemical Identity: What Can Actually Be VerifiedRetatrutide has no findable PubChem record. What that means for its reported CAS and molecular weight, and why one widely cited identifier is tirzepatide's.
- How the Incretin Field Got HereExenatide from lizard venom, liraglutide's fatty acid, semaglutide's weekly dosing, then multi-agonism. Each generation solved the previous one's limit.
- Retatrutide Storage and StabilityA lipidated 39-mer is more surface-active than most peptides. Why foaming matters more here, and what the fatty acid changes about handling.